ReleaseWire Connect

Biopharmaceuticals are drugs produced from genetically modified source, which are mainly proteins and nucleic acids. According to IMS Health Market Prognosis, the total market size of pharmaceutical industry was approximately $962.1 billion in 2012. The biopharmaceuticals drug market was $149 billion in 2010. The factors driving the market are, increase in regulatory approvals for biotechnology products. One such product is the recombinant DNA-based products, which has high rates of approval from regulatory authorities. The opportunities of this market are the ageing population and increase in the number of diseases. The challenges of this market are the reimbursement and pricing policy that are the limiting factors in the launch of high priced drugs.

According to the American lung association, the number of deaths due to lung cancer has increased ~3.5% from ~152,156 cases in 1999 to ~157,499 in 2012. Furthermore, it is estimated that ~158,040 Americans are would die due to lung cancer by 2015. According to the American Society of cancer, non small-cell lung cancer accounts for ~85% to 90% of overall lung cancer cases and the trend is expected to grow with the same momentum. Thus, a large patient base of non small-cell lung cancer depicts the unmet need for diagnosis and treatment. It has been observed that non small-cell lung cancer is the most prevalent type of lung cancer commonly caused due to active and passive smoking.

In 2011, the global therapeutic vaccines market was valued at $294 million. This vaccine has expanded the horizon of chronic disease treatment. However, there is a need to get a vaccine for specific disease to be approved by the FDA. Increasing cases of chronic diseases and need for effective treatment is acting as key driver for this market. Various pharmaceutical companies are working to develop novel vaccines for diseases such as lung cancer, breast cancer, Alzheimer, etc. However, these vaccine developments are in pipeline and yet to be commercialized.

Computerized physician order entry is a process of entering prescription and an information about medical services into computer systems by medical practitioners. This information is communicated to medical staff and other departments through a computer network. Faster transfer of prescription to other departments, electronic records of prescription, clinical decision support systems, and economic efficiency are benefits of computerized physician order entry system over traditional hand-written or verbally communicated methods. The system is gaining prominence due to reduction the errors, such as poor handwriting in ordering and transcribing medicines to the patients.

The global BPaaS market was valued at $3,916 million in 2016, and is projected to reach at $15,144 million by 2023, growing at a CAGR of 21.8% from 2017 to 2023.

High penetration of conventional drugs used in the treatment of fungal diseases is reducing the growth for anti-fungal agent market. Though these restraints are dominating the market, the application of anti fungal drugs market has initiated the growth of anti fungal agent market. The challenges faced by this market are expected to resolve, as companies are concentrating on advancement in technologies that reduces the cost and increases the efficiency of the treatment. The report provides intelligence on patent analysis that provides forecasted market trends for anti fungal agents. The report also provides intelligence about competitive landscape for key companies engaged in this business.

The Histone deactylase inhibitor (HDAC) is a molecule that consists of different compounds that form a group of anticancer agents. The parent epigenetic market of HDAC is expected to grow at a CAGR of around 30% worldwide from 2013 to 2020. The factors driving this Histone Deacetylase Inhibitors market are increase in cancer incidences, ongoing research and development for the treatment of cancer, other diseases, and the need to improve the effectiveness of new therapies. The major limitation of this market is reimbursement and uncertainty issues. The opportunities for this market are increase in collaborations and huge investments in manufacturing which will ensure significant growth.

According to IMS Health Market Prognosis, the total market size of pharmaceutical industry was approximately $962.1 billion in 2012. This shows growth opportunities for protein therapeutics market. High efficiency of protein therapeutics with fewer side effects is driving the protein therapeutics market. For example, Approximately 17.7 adults consumed oral medication (Pills or insulin) for diabetes in 2011. Protein therapeutics market growth is hindered by adverse side effects in chronic diseases and cost of production.

The drivers that support the growth of ophthalmic drug market are aging population, changing lifestyle, technological changes, and increase in healthcare spending. Lack of awareness among people regarding eye diseases and disorders, absence of health insurance in developing countries are some of the challenges faced by the ophthalmic drugs market.

The rise in the incidences of zoonotic diseases are affecting humans and has led to increased interest in companion animal vaccines. Advancement in this area is mainly due to emergence of new zoonotic diseases, investment by government bodies and increased expenditures on animal health by pet lovers.